• Borson, N.D., Lacy, M.Q. & Wettstein, P.J. (2002) Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma. Blood, 100, 46294639.
  • Dorfler, P. & Busslinger, M. (1996) C-terminal activating and inhibitory domains determine the transactivation potential of BSAP (Pax-5), Pax-2 and Pax-8. The EMBO Journal, 15, 19711982.
  • Horcher, M., Souabni, A. & Busslinger, M. (2001) Pax5/BSAP maintains the identity of B cells in late B lymphopoiesis. Immunity, 14, 779790.
  • Oppezzo, P., Dumas, G., Lalanne, A.I., Payelle-Brogard, B., Magnac, C., Pritsch, O., Dighiero, G. & Vuillier, F. (2005) Different isoforms of BSAP regulates of AID in normal and chronic lymphocytic leukemia B cells. Blood, 105, 24952503.
  • Robichaud, G.A., Nardini, M., Laflamme, M., Cuperlovic-Culf, M. & Ouellette, R.J. (2004) Human Pax5-terminal isoforms possess distinct transactivation properties and are differentially modulated in normal and malignant B cells. The Journal of Biological Chemistry, 279, 4995649963.
  • Sanz, E., Alvarez-Mon, M., Martinez-A, C. & De La Hera, A (2003) Human cord blood CD34+Pax-5+ B-cell progenitors: single-cell analyses of their gene expression profiles. Blood, 101, 34243430.
  • Schebesta, M., Heavey, B. & Busslinger, M. (2002) Transcriptional control of B-cell development. Current Opinion in Immunology, 14, 216223.
  • Tiacci, E., Pileri, S., Orleth, A., Pacini, R., Tabarrini, A., Frenguelli, F., Liso, A., Diverio, D., Lo-Coco, F. & Falini, B. (2004) PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. Cancer Research, 64, 73997404.